# A Study to Evaluate the Efficacy and Safety of Risperidone (R064766) in Children and Adolescents With Irritability Associated With Autistic Disorder

> **NCT01624675** · PHASE3 · COMPLETED · sponsor: **Janssen Pharmaceutical K.K.** · enrollment: 39 (actual)

## Conditions studied

- Autistic Disorder in Children and Adolescents

## Interventions

- **DRUG:** Risperidone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01624675
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2015-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01624675

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01624675, "A Study to Evaluate the Efficacy and Safety of Risperidone (R064766) in Children and Adolescents With Irritability Associated With Autistic Disorder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01624675. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*